Skip to main content

Table 3 Comparison between patients with composite end-point (CEP+) and without (CEP−)

From: Multimodal assessment of right ventricle overload-metabolic and clinical consequences in pulmonary arterial hypertension

 

CEP (+) patients

CEP (−) patients

p-value

Patients, n

18

9

 

BNP, pg/ml

241 [22–925]

62 [36–435]

0.19

6MWT distance, m

358.8 ± 97.2

443.6 ± 95.4

0.06

SUVRV/SUVLV ratio

1.29 ± 0.78

0.51 ± 0.39

0.003

RVEF, %

40.9 ± 8.8

52.5 ± 8.4

0.004

TAPSE, mm

17.9 ± 4.0

21.3 ± 4.2

0.07

PAC, ml/mmHg

2.0 ± 0.9

3.3 ± 2.3

0.06

mPAP, mmHg

56.3 ± 15.8

33.1 ± 8.2

 < 0.001

PVR, wood units

10.9 ± 5.3

4.3 ± 2.3

 < 0.001

RV GLS, %

− 13.5 ± 7

− 22.2 ± 3.8

0.001

RV GLS/PASP, %/mmHg

− 0.16 ± 0.08

− 0.44 ± 0.11

 < 0.001

RV GLS/PVR, %/WU

− 1.75 ± 1.68

− 6.4 ± 3.1

 < 0.001

RVGLS*PAC, %*mmHg/ml

− 26 ± 16.7

− 75.1 ± 54.3

 < 0.001

RVEF/PASP, %*mmHg

0.51 ± 0.21

1.02 ± 0.36

 < 0.001

RVEF/PVR, %*WU

5.37 ± 4.16

15.72 ± 8.26

 < 0.001

RVEF*PAC, %/mmHg/ml

85.3 ± 50.4

181.9 ± 133.1

0.006

TAPSE/RVSP (echo/echo)

0.30 ± 0.17

0.44 ± 0.21

0.012

TAPSE/RVSP (CMR/echo)

0.28 ± 0.16

0.55 ± 0.21

0.03

RV GLS/RVSP (CMR/echo)

− 0.22 ± 0.19

− 0.57 ± 0.21

0.03

RVEF/RVSP (CMR/echo)

0.68 ± 0.39

1.26 ± 0.58

0.01

  1. 6MWT six minute walk test distance, BNP serum brain natriuretic peptide, BSA body surface area, CEP composite end-point, CI cardiac index, CMR cardiac magnetic resonance, echo echocardiography, GLS global longitudinal strain, FAC fractional area change, LV left ventricle, mPAP mean pulmonary artery pressure, PAC pulmonary arterial compliance, PASP pulmonary artery systolic pressure, PET positron emission tomography, PVR pulmonary vascular resistance, RV right ventricle, RVEF right ventricle ejection fraction, RVSP right ventricle systolic pressure obtained by echocardiography, SUV standardized uptake value, TAPSE tricuspid annular plane systolic excursion, WHO World Health Organisation